Cited by 279

The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.

Boron Chemicals in Diagnosis and Therapeutics

Open access

Das, Bhaskar C, Thapa, Pritam, Karki, Radha, Schinke, Caroline, Das, Sasmita, Kambhampati, Suman, Banerjee, Sushanta K, Van Veldhuizen, Peter, Verma, Amit, Weiss, Louis M, Evans, Todd·2013·Future Medicinal Chemistry

DOI 10.4155/fmc.13.38

Open this paper in CoChat — free account

Abstract

Advances in the field of boron chemistry have expanded the application of boron from material use to medicine. Boron-based drugs represent a new class of molecules that possess several biomedical applications including use as imaging agents for both optical and nuclear imaging as well as therapeutic agents with anticancer, antiviral, antibacterial, antifungal and other disease-specific activities. For example, bortezomib (Velcade(®)), the only drug in clinical use with boron as an active element, was approved in 2003 as a proteasome inhibitor for the treatment of multiple myeloma and non-Hodgkin's lymphoma. Several other boron-based compounds are in various phases of clinical trials, which illustrates the promise of this approach for medicinal chemists working in the area of boron chemistry. It is expected that in the near future, several boron-containing drugs should become available in the market with better efficacy and potency than existing drugs. This article discusses the current status of the development of boron-based compounds as diagnostic and therapeutic agents in humans.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.4155/fmc.13.38

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Free Radicals in the Physiological Control of Cell Function
Dröge, W. (2002) · Physiological Reviews · doi:10.1152/physrev.00018.2001 · Cited by 9,855
Oxidative stress, inflammation, and cancer: How are they linked?
Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.006 · Cited by 5,441
Mitochondrial formation of reactive oxygen species
Turrens, J. F. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.049478 · Cited by 5,084
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Boron Nitride Nanotubes and Nanosheets
Golberg, D., Bando, Y., Huang, Y., Terao, T., Mitome, M., Tang, C., & Zhi, C. (2010) · ACS Nano · doi:10.1021/nn1006495 · Cited by 2,341
Three Decades of β-Lactamase Inhibitors
Drawz, S. M., & Bonomo, R. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00037-09 · Cited by 1,709
Production of Reactive Oxygen Species by Mitochondria
Chen, Q., Vazquez, E. J., Moghaddas, S., Hoppel, C. L., & Lesnefsky, E. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304854200 · Cited by 1,616
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
Reactive oxygen species: role in the development of cancer and various chronic conditions.
Waris, G., & Ahsan, H. (2006) · Journal of Carcinogenesis · doi:10.1186/1477-3163-5-14 · Cited by 1,459
Generation of reactive oxygen species by the mitochondrial electron transport chain
Liu, Y., Fiskum, G., & Schubert, D. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2002.00744.x · Cited by 1,260
The proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201
Oxidative stress and Alzheimer disease
Christen, Y. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.2.621s · Cited by 1,158
The Chemistry of Neutron Capture Therapy
Soloway, A. H., Tjarks, W., Barnum, B. A., Rong, F.-G., Barth, R. F., Codogni, I. M., & Wilson, J. G. (1998) · Chemical Reviews · doi:10.1021/cr941195u · Cited by 1,143
The emerging role of lysophosphatidic acid in cancer
Mills, G. B., & Moolenaar, W. H. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1143 · Cited by 1,094
Neurodegenerative diseases and oxidative stress
Emerit, J., Edeas, M., & Bricaire, F. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2003.11.004 · Cited by 1,031
The respiratory burst of phagocytes.
Babior, B. M. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111249 · Cited by 898
An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations
Kregel, K. C., & Zhang, H. J. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00327.2006 · Cited by 883
mtDNA mutations increase tumorigenicity in prostate cancer
Petros, J. A., Baumann, A. K., Ruiz-Pesini, E., Amin, M. B., Sun, C. Q., Hall, J., Lim, S., Issa, M. M., Flanders, W. D., Hosseini, S. H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408894102 · Cited by 836
Signaling Functions of Reactive Oxygen Species
Forman, H. J., Maiorino, M., & Ursini, F. (2010) · Biochemistry · doi:10.1021/bi9020378 · Cited by 827
Reactive oxygen species in cardiovascular disease
Sugamura, K., & Keaney (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.05.004 · Cited by 769
A Selective, Cell-Permeable Optical Probe for Hydrogen Peroxide in Living Cells
Chang, M. C. Y., Pralle, A., Isacoff, E. Y., & Chang, C. J. (2004) · Journal of the American Chemical Society · doi:10.1021/ja0441716 · Cited by 651
Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy
Kane, R. C., Bross, P. F., Farrell, A. T., & Pazdur, R. (2003) · The Oncologist · doi:10.1634/theoncologist.8-6-508 · Cited by 628
Boronate-Based Fluorescent Probes for Imaging Cellular Hydrogen Peroxide
Miller, E. W., Albers, A. E., Pralle, A., Isacoff, E. Y., & Chang, C. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja054474f · Cited by 591
Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools
Greenbaum, D., Medzihradszky, K. F., Burlingame, A., & Bogyo, M. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00014-4 · Cited by 581
Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
Orlowski, R. Z., & Kuhn, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2218 · Cited by 578
Mechanisms that regulate production of reactive oxygen species by cytochrome P450
ZANGAR, R. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.01.018 · Cited by 555
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-κB inhibition
Houston, M. A., Abendroth, K., Baldwin, A. S., & Liu, R. (2001) · PubMed · doi:10.17615/k359-fr77 · Cited by 547
Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer
Barth, R. F., H Vicente, M., Harling, O. K., Kiger, W., Riley, K. J., Binns, P. J., Wagner, F. M., Suzuki, M., Aihara, T., Kato, I., et al. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-146 · Cited by 531
Autotaxin, a Secreted Lysophospholipase D, Is Essential for Blood Vessel Formation during Development
van Meeteren, L. A., Ruurs, P., Stortelers, C., Bouwman, P., van Rooijen, M. A., Pradère, J. P., Pettit, T. R., Wakelam, M. J. O., Saulnier-Blache, J. S., Mummery, C. L., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02419-05 · Cited by 529
A Palette of Fluorescent Probes with Varying Emission Colors for Imaging Hydrogen Peroxide Signaling in Living Cells
Dickinson, B. C., Huynh, C., & Chang, C. J. (2010) · Journal of the American Chemical Society · doi:10.1021/ja1014103 · Cited by 515
Boronic acid compounds as potential pharmaceutical agents
Yang, W., Gao, X., & Wang, B. (2003) · Medicinal Research Reviews · doi:10.1002/med.10043 · Cited by 502
Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Kupperman, E., Lee, E. C., Cao, Y., Bannerman, B., Fitzgerald, M., Berger, A., Yu, J., Yang, Y., Hales, P., Bruzzese, F., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2766 · Cited by 499
Molecular targets of oxidative stress
Avery, S. V. (2011) · Biochemical Journal · doi:10.1042/bj20101695 · Cited by 474
Autotaxin Stabilizes Blood Vessels and Is Required for Embryonic Vasculature by Producing Lysophosphatidic Acid
Tanaka, M., Okudaira, S., Kishi, Y., Ohkawa, R., Iseki, S., Ota, M., Noji, S., Yatomi, Y., Aoki, J., & Arai, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605142200 · Cited by 457
Molecular imaging of hydrogen peroxide produced for cell signaling
Miller, E. W., Tulyathan, O., Isacoff, E. Y., & Chang, C. J. (2007) · Nature Chemical Biology · doi:10.1038/nchembio871 · Cited by 450
Boron Containing Compounds as Protease Inhibitors
Smoum, R., Rubinstein, A., Dembitsky, V. M., & Srebnik, M. (2012) · Chemical Reviews · doi:10.1021/cr608202m · Cited by 450
In vivo imaging of hydrogen peroxide production in a murine tumor model with a chemoselective bioluminescent reporter
Van de Bittner, G. C., Dubikovskaya, E. A., Bertozzi, C. R., & Chang, C. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012864107 · Cited by 403
Histone Deacetylase Inhibition Selectively Alters the Activity and Expression of Cell Cycle Proteins Leading to Specific Chromatin Acetylation and Antiproliferative Effects
Sambucetti, L. C., Fischer, D. D., Zabludoff, S., Kwon, P. O., Chamberlin, H., Trogani, N., Xu, H., & Cohen, D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34940 · Cited by 390
Therapeutic Potential of Boron-Containing Compounds
Baker, S. J., Ding, C. Z., Akama, T., Zhang, Y.-K., Hernandez, V., & Xia, Y. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.71 · Cited by 373
Role of Oxidant Species in Aging
Stadtman, E. R. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043365341 · Cited by 368
Basic Mechanisms of Oxidative Stress and Reactive Oxygen Species in Cardiovascular Injury
Papaharalambus, C. A., & Griendling, K. K. (2007) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2006.11.005 · Cited by 351
Oxidative stress and cardiovascular disease: Novel tools give (free) radical insight
Fearon, I. M., & Faux, S. P. (2009) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2009.05.013 · Cited by 328
Discovery of a New Boron-Containing Antifungal Agent, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the Potential Treatment of Onychomycosis
Baker, S. J., Zhang, Y.-K., Akama, T., Lau, A., Zhou, H., Hernandez, V., Mao, W., Alley, M. R. K., Sanders, V., & Plattner, J. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603724 · Cited by 314
Hydrogen Peroxide Inducible DNA Cross-Linking Agents: Targeted Anticancer Prodrugs
Kuang, Y., Balakrishnan, K., Gandhi, V., & Peng, X. (2011) · Journal of the American Chemical Society · doi:10.1021/ja2073824 · Cited by 311
Bortezomib Sensitizes Pancreatic Cancer Cells to Endoplasmic Reticulum Stress-Mediated Apoptosis
Nawrocki, S. T., Carew, J. S., Pino, M. S., Highshaw, R. A., Dunner, K., Huang, P., Abbruzzese, J. L., & McConkey, D. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2370 · Cited by 309
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline
Richardson, P. G., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07573.x · Cited by 305
SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis
Jacobs, R. T., Nare, B., Wring, S. A., Orr, M. D., Chen, D., Sligar, J. M., Jenks, M. X., Noe, R. A., Bowling, T. S., Mercer, L. T., et al. (2011) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0001151 · Cited by 305
Hepatitis C: an epidemiological review
Memon, M. I., & Memon, M. A. (2002) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2002.00329.x · Cited by 293
Chemical Approaches for Functionally Probing the Proteome
Greenbaum, D., Baruch, A., Hayrapetian, L., Darula, Z., Burlingame, A., Medzihradszky, K. F., & Bogyo, M. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t100003-mcp200 · Cited by 291
Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy
Dick, L. R., & Fleming, P. E. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.01.008 · Cited by 273
Synthesis of cellulose derivatives containing the dihydroxyboryl group and a study of their capacity to form specific complexes with sugars and nucleic acid components
Weith, H. L., Wiebers, J. L., & Gilham, P. T. (1970) · Biochemistry · doi:10.1021/bi00824a021 · Cited by 268
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib
Piva, R., Ruggeri, B., Williams, M., Costa, G., Tamagno, I., Ferrero, D., Giai, V., Coscia, M., Peola, S., Massaia, M., et al. (2008) · Blood · doi:10.1182/blood-2007-07-100651 · Cited by 252
Hydrogen Peroxide in Human Urine: Implications for Antioxidant Defense and Redox Regulation
Long, L. H., Evans, P. J., & Halliwell, B. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1263 · Cited by 209
Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation
Albers, H. M. H. G., Dong, A., van Meeteren, L. A., Egan, D. A., Sunkara, M., van Tilburg, E. W., Schuurman, K., van Tellingen, O., Morris, A. J., Smyth, S. S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001529107 · Cited by 204
Mitochondrial-Mediated Disregulation of Ca2+ Is a Critical Determinant of Velcade (PS-341/Bortezomib) Cytotoxicity in Myeloma Cell Lines
Landowski, T. H., Megli, C. J., Nullmeyer, K. D., Lynch, R. M., & Dorr, R. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3684 · Cited by 202
Regulation of Lung Cancer Cell Migration and Invasion by Reactive Oxygen Species and Caveolin-1
Luanpitpong, S., Talbott, S. J., Rojanasakul, Y., Nimmannit, U., Pongrakhananon, V., Wang, L., & Chanvorachote, P. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.124958 · Cited by 201
Fluorescent BODIPY-Based Zn(II) Complex as a Molecular Probe for Selective Detection of Neurofibrillary Tangles in the Brains of Alzheimer’s Disease Patients
Ojida, A., Sakamoto, T., Inoue, M.-A., Fujishima, S.-H., Lippens, G., & Hamachi, I. (2009) · Journal of the American Chemical Society · doi:10.1021/ja9008369 · Cited by 186
A critical assessment of boron target compounds for boron neutron capture therapy
Hawthorne, M. F., & Lee, M. W. (2003) · Journal of Neuro-oncology · doi:10.1007/bf02699932 · Cited by 185
Selective Recognition of Protein Tetraserine Motifs with a Cell-Permeable, Pro-fluorescent Bis-boronic Acid
Halo, T. L., Appelbaum, J., Hobert, E. M., Balkin, D. M., & Schepartz, A. (2009) · Journal of the American Chemical Society · doi:10.1021/ja807872s · Cited by 182
Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)
Seiwert, S. D., Andrews, S. W., Jiang, Y., Serebryany, V., Tan, H., Kossen, K., Rajagopalan, P. T. R., Misialek, S., Stevens, S. K., Stoycheva, A., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00699-08 · Cited by 175
Folate Functionalized Boron Nitride Nanotubes and their Selective Uptake by Glioblastoma Multiforme Cells: Implications for their Use as Boron Carriers in Clinical Boron Neutron Capture Therapy
Ciofani, G., Raffa, V., Menciassi, A., & Cuschieri, A. (2009) · Nanoscale Research Letters · doi:10.1007/s11671-008-9210-9 · Cited by 174
Current Challenges in Antimicrobial Chemotherapy: Focus on β-Lactamase Inhibition
Bebrone, C., Lassaux, P., Vercheval, L., Sohier, J.-S., Jehaes, A., Sauvage, E., & Galleni, M. (2010) · Drugs · doi:10.2165/11318430-000000000-00000 · Cited by 159
ROS-activated Anticancer Prodrugs: a New Strategy for tumor-specific Damage
Peng, X., & Gandhi, V. V. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.61 · Cited by 151
Structure-Based Enhancement of Boronic Acid-Based Inhibitors of AmpC β-Lactamase
Weston, G. S., Blázquez, J., Baquero, F., & Shoichet, B. K. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980343w · Cited by 142
Dietary boron: Progress in establishing essential roles in human physiology
Hunt, C. D. (2012) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2012.03.014 · Cited by 139
Bortezomib as a Potential Treatment for Prostate Cancer
Papandreou, C. N., & Logothetis, C. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2707 · Cited by 135
Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry
Génin, E., Reboud‐Ravaux, M., & Vidal, J. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790725515 · Cited by 129
Hepatitis C virus NS3/4A protease
Kwong, A. D., Kim, J. L., Rao, G., Lipovšek, D., & Raybuck, S. A. (1998) · Antiviral Research · doi:10.1016/s0166-3542(98)00043-6 · Cited by 126
Structure, Function, and Inhibition along the Reaction Coordinate of CTX-M β-Lactamases
Chen, Y., Shoichet, B. K., & Bonnet, R. (2005) · Journal of the American Chemical Society · doi:10.1021/ja042850a · Cited by 120
Biologically active compounds of semi-metals
Řezanka, T., & Sigler, K. (2007) · Phytochemistry · doi:10.1016/j.phytochem.2007.09.018 · Cited by 119
Crystal Structures of the Human and Fungal Cytosolic Leucyl-tRNA Synthetase Editing Domains: A Structural Basis for the Rational Design of Antifungal Benzoxaboroles
Seiradake, E., Mao, W., Hernandez, V. S., Baker, S. J., Plattner, J. J., Alley, M. R. K., & Cusack, S. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.04.073 · Cited by 109
Clinical consequences of hepatitis C virus infection
Zoulim, F., Chevallier, M., Maynard, M., & TREPO, C. G. (2002) · Reviews in Medical Virology · doi:10.1002/rmv.371 · Cited by 109
A Practical Update on the Use of Bortezomib in the Management of Multiple Myeloma
Miguel, J. F. S., Bladé, J., Boccadoro, M., Cavenagh, J. D., Glasmacher, A., Jagannath, S., Lonial, S., Orlowski, R. Z., Sonneveld, P., & Ludwig, H. (2006) · The Oncologist · doi:10.1634/theoncologist.11-1-51 · Cited by 109
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells
Codony-Servat, J., Tapia, M. A., Bosch, M., Oliva, C., Domingo-Domenech, J., Mellado, B., Rolfe, M., Ross, J. S., Gascon, P., Rovira, A., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0147 · Cited by 104
Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma
Bianchi, A. S., Gasparri, F., Galvani, A. P., Nici, L. L., Darnowski, J. W., Barbone, D., Fennell, D. A., Gaudino, G., Porta, C., & Mutti, L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0536 · Cited by 94
Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer
Eager, R., Cunningham, C. C., Senzer, N. N., Richards, D., Raju, R. N., Jones, B. N., Uprichard, M. J., & Nemunaitis, J. J. (2009) · Clinical Oncology · doi:10.1016/j.clon.2009.04.007 · Cited by 92
Incorporating Bortezomib into the Treatment of Lung Cancer
Davies, A. M., Lara, P. N., Mack, P. C., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0334 · Cited by 89
Novel Matrix Metalloproteinase Inhibitor [18F]Marimastat-Aryltrifluoroborate as a Probe for In vivo Positron Emission Tomography Imaging in Cancer
Keller, U. A. D., Bellac, C. L., Li, Y., Lou, Y., Lange, P. F., Ting, R., Harwig, C., Kappelhoff, R., Dedhar, S., Adam, M. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1584 · Cited by 88
ROS‐Inducible DNA Cross‐Linking Agent as a New Anticancer Prodrug Building Block
Cao, S., Wang, Y., & Peng, X. (2012) · Chemistry - A European Journal · doi:10.1002/chem.201200075 · Cited by 88
New therapeutic options for onychomycosis
Gupta, A. K., & Simpson, F. C. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.681779 · Cited by 87
In Vivo and In Vitro Effects of Boron and Boronated Compounds
Benderdour, M., Bui-Van, T., Dıcko, A., & Belleville, F. (1998) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/s0946-672x(98)80014-x · Cited by 83
Design, Synthesis, and Biological Activity of Boronic Acid-Based Histone Deacetylase Inhibitors
Suzuki, N., Suzuki, T., Ota, Y., Nakano, T., Kurihara, M., Okuda, H., Yamori, T., Tsumoto, H., Nakagawa, H., & Miyata, N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900125m · Cited by 82
Urinary hydrogen peroxide: a probable marker of oxidative stress in malignancy
Banerjee, D., Madhusoodanan, U. K., Nayak, S. S., & Jacob, J. (2003) · Clinica Chimica Acta · doi:10.1016/s0009-8981(03)00236-5 · Cited by 77
m-Carborane bisphenol structure as a pharmacophore for selective estrogen receptor modulators
Ogawa, T., Ohta, K., Yoshimi, T., Yamazaki, H., Suzuki, T., Ohta, S., & Endo, Y. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.05.032 · Cited by 70
Glycosylated haemoglobin and plasma glycoprotein assays by affinity chromatography
Willey, D. G., Rosenthal, M. A., & Caldwell, S. (1984) · Diabetologia · doi:10.1007/bf00253503 · Cited by 69
Potent and Selective Peptidyl Boronic Acid Inhibitors of the Serine Protease Prostate-Specific Antigen
LeBeau, A. M., Singh, P., Isaacs, J. T., & Denmeade, S. R. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.05.020 · Cited by 67
Talabostat
Cunningham, C. C. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.9.1459 · Cited by 63
Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1α inhibitors
Shimizu, K., Maruyama, M., Yasui, Y., Minegishi, H., Ban, H. S., & Nakamura, H. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.12.037 · Cited by 62
Application of PET/CT in the Development of Novel Anticancer Drugs
Boss, D. S., Olmos, R. A. V., Sinaasappel, M., Beijnen, J. H., & Schellens, J. H. M. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0097 · Cited by 60
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines
Schmid, P., Kühnhardt, D., Kiewe, P. M., Lehenbauer-Dehm, S., Schippinger, W., Greil, R., Lange, W., Preiss, J., Niederle, N., Brossart, P., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm569 · Cited by 54
The formulation of polyhedral boranes for the boron neutron capture therapy of cancer
Calabrese, G., Nesnas, J., Barbu, E., Fatouros, D. G., & Tsibouklis, J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.014 · Cited by 46
Synthesis and evaluation of novel α-amino cyclic boronates as inhibitors of HCV NS3 protease
Li, X., Zhang, Y.-K., Liu, Y., Ding, C. Z., Li, Q., Zhou, Y., Plattner, J. J., Baker, S. J., Qian, X., Fan, D., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.04.129 · Cited by 46
Synthesis and Evaluation of 3-(Dihydroxyboryl)benzoic Acids as d , d -Carboxypeptidase R39 Inhibitors
Inglis, S. R., Zervosen, A., Woon, E. C. Y., Gerards, T., Teller, N., Fischer, D. S., Luxen, A., & Schofield, C. J. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9009718 · Cited by 45
Boron as a platform for new drug design
Ciani, L., & Ristori, S. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.717530 · Cited by 44
BNNT-Mediated Irreversible Electroporation: Its Potential on Cancer Cells
Raffa, V., Riggio, C., Smith, M. W., et al. (2012) · Technology in Cancer Research & Treatment · doi:10.7785/tcrt.2012.500258 · Cited by 44
Novel Retinoic Acid Receptor Alpha Agonists for Treatment of Kidney Disease
Zhong, Y., Wu, Y., Liu, R., Li, Z., Chen, Y., Evans, T., Chuang, P. Y., Das, B. C., & He, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027945 · Cited by 42
Self-citation
Discovery of 3-acetyl-4-hydroxy-2-pyranone derivatives and their difluoridoborate complexes as a novel class of HIV-1 integrase Inhibitors
Ramkumar, K., Tambov, K. V., Gundla, R., Manaev, A. V., Yarovenko, V. N., Traven, V. F., & Neamati, N. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.08.067 · Cited by 41
Boron-containing antibacterial agents: effects on growth and morphology of bacteria under various culture conditions
Bailey, P., Cousins, G., Snow, G. A., & White, A. J. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.17.4.549 · Cited by 41
Assembling Ligands In Situ Using Bioorthogonal Boronate Ester Synthesis
Shin, S. B. Y., Almeida, R. D., Gerona‐Navarro, G., Bracken, C., & Jaffrey, S. R. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.09.008 · Cited by 39
Potent inhibitors of HCV-NS3 protease derived from boronic acids
Venkatraman, S., Wu, W., Prongay, A., GIRIJAVALLABHAN, V. M., & Njoroge, F. G. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.124 · Cited by 36
A novel carborane analog, BE360, with a carbon-containing polyhedral boron-cluster is a new selective estrogen receptor modulator for bone
Hirata, M., Inada, M., Matsumoto, C., Takita, M., Ogawa, T., Endo, Y., & Miyaura, C. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.01.033 · Cited by 36
Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates
Li, X., Zhang, Y.-K., Liu, Y., Ding, C. Z., Zhou, Y., Li, Q., Plattner, J. J., Baker, S. J., Zhang, S., Kazmierski, W. M., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.08.022 · Cited by 36
Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors
Hasabelnaby, S. M., Goudah, A., Agarwal, H. K., alla, M. S. M. A., & Tjarks, W. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.07.033 · Cited by 32
Decitabine Up-regulates S100A2 Expression and Synergizes with IFN-γ to Kill Uveal Melanoma Cells
Gollob, J., & Sciambi, C. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0816 · Cited by 31
Hepatitis C and hepatocellular carcinoma
Yao, F. Y., & Terrault, N. A. (2001) · Current Treatment Options in Oncology · doi:10.1007/s11864-001-0069-6 · Cited by 31
Target identification of bioactive compounds
Tashiro, E., & Imoto, M. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.10.081 · Cited by 29
The dipeptidyl peptidase‐4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus
Garcia‐Soria, G., González-Gálvez, G., Argoud, G., Gerstman, M., Littlejohn, T. W., Schwartz, S. L., O'Farrell, A. M., Li, X., Cherrington, J. M., Bennett, C., et al. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00868.x · Cited by 29
Synthesis of boronic acid derivatives of tyropeptin: Proteasome inhibitors
Watanabe, T., Momose, I., Abe, M., Abe, H., Sawa, R., Umezawa, Y., Ikeda, D., Takahashi, Y., & Akamatsu, Y. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.02.117 · Cited by 26
Utilization of fluorescent probes for the quantification and identification of subcellular proteomes and biological processes regulated by lipid peroxidation products
Cummins, T. D., Higdon, A. N., Kramer, P. A., Chacko, B. K., Riggs, D. W., Salabei, J. K., Dell’Italia, L. J., Zhang, J., Darley-Usmar, V. M., & Hill, B. G. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.08.014 · Cited by 26
Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib
Voutsadakis, I. A., Patrikidou, A., Tsapakidis, K., Karagiannaki, A., Hatzidaki, E., Stathakis, N. E., & Papandreou, C. N. (2010) · International Journal of Colorectal Disease · doi:10.1007/s00384-010-0939-0 · Cited by 26
A Forward Chemical Screen in Zebrafish Identifies a Retinoic Acid Derivative with Receptor Specificity
Das, B. C., McCartin, K., Liu, T.-C., Peterson, R. T., & Evans, T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010004 · Cited by 26
Self-citation
Oral Toxicity of Boric Acid and Other Boron Compounds to Immature Cat Fleas (Siphonaptera: Pulicidae)
Klotz, J. H., Moss, J., Zhao, R., et al. (1994) · Journal of Economic Entomology · doi:10.1093/jee/87.6.1534 · Cited by 15
Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity
Hu, W., Zheng, R.-R., Cui, H., Yue, D., Wang, Y., & Jiang, Y. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2012.59 · Cited by 10
Design and synthesis of boron containing potential pan-RAR inverse agonists
Das, B. C., Tang, X., & Evans, T. (2012) · Tetrahedron Letters · doi:10.1016/j.tetlet.2011.12.118 · Cited by 8
Self-citation
Design and synthesis of 3,5-disubstituted 1,2,4-oxadiazole containing retinoids from a retinoic acid receptor agonist
Das, B. C., Tang, X., Sanyal, S., Mohapatra, S., Rogler, P. J., Nayak, S., & Evans, T. (2011) · Tetrahedron Letters · doi:10.1016/j.tetlet.2011.03.011 · Cited by 7
Self-citation

Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury
Hong, Q., Zhang, L., Das, B., Li, Z., Liu, B., Cai, G., Chen, X., Chuang, P. Y., He, J. C., & Lee, K. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.008 · Cited by 222
Self-citation

See all 279

Authors: Das, B. C., Thapa, P., Karki, R., Schinke, C., Das, S., Kambhampati, S., Banerjee, S. K., Van Veldhuizen, P., Verma, A., Weiss, L. M., & Evans, T.
Venue: Future Medicinal Chemistry
Publisher: Informa UK Limited
Published: 2013-04
Volume: 5
Issue: 6
Pages: 653-676
ISSN: 1756-8919 (ISSN-L)
1756-8927
DOI: 10.4155/fmc.13.38
OpenAlex: W1979417745
Cited by: 279
References: 115
FWCI: 9.27
Type: journal article
Language: en
Open access: green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

Boron Chemicals in Diagnosis and Therapeutics

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources